Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Net Income towards Common Stockholders (2020 - 2025)

Vivos Therapeutics' Net Income towards Common Stockholders history spans 6 years, with the latest figure at -$7.0 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at -$7.0 million for Q4 2025, down 145.99% from a year ago — trailing twelve months through Dec 2025 was -$21.2 million (down 90.65% YoY), and the annual figure for FY2025 was -$21.2 million, down 90.64%.
  • Net Income towards Common Stockholders for Q4 2025 was -$7.0 million at Vivos Therapeutics, down from -$5.4 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.7 million in Q1 2023 to a low of -$7.4 million in Q4 2021.
  • The 5-year median for Net Income towards Common Stockholders is -$4.6 million (2023), against an average of -$4.5 million.
  • The sharpest move saw Net Income towards Common Stockholders plummeted 164.3% in 2021, then surged 68.05% in 2023.
  • Year by year, Net Income towards Common Stockholders stood at -$7.4 million in 2021, then rose by 17.64% to -$6.1 million in 2022, then skyrocketed by 30.05% to -$4.3 million in 2023, then skyrocketed by 33.62% to -$2.8 million in 2024, then tumbled by 145.99% to -$7.0 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$7.0 million, -$5.4 million, and -$5.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.